Tenet Healthcare upgraded to BB- by S&P on improved performance

S&P Global Ratings upgraded Tenet Healthcare Corp. to 'BB-' from 'B+' with a positive outlook, citing the company's significantly improved credit profile driven by its strategic plan. This plan involved expanding its high-profit ambulatory surgery business, rationalizing its hospital portfolio, and substantially reducing leverage to 3.5x from 5.2x, aided by $5 billion in hospital sales proceeds. S&P anticipates Tenet will maintain leverage below 4x and generate $1.2 billion-$1.4 billion in annual free cash flow, signaling a strengthened financial position and operational efficiency despite potential health policy developments.

Analysis

S&P Global Ratings has upgraded Tenet Healthcare Corp. to 'BB-' from 'B+' with a positive outlook, signaling strong validation of the company's multiyear strategic transformation. The upgrade is underpinned by a significant improvement in Tenet's credit profile, driven by the successful rationalization of its hospital portfolio—which generated $5 billion in proceeds over two years—and a strategic pivot toward its higher-margin ambulatory surgery center (ASC) business. This shift has materially de-risked the balance sheet, with leverage decreasing from 5.2x at year-end 2023 to a projected 3.5x as of March 31, 2025. The ASC segment now accounts for approximately 24% of consolidated revenue and a larger share of profitability. Looking ahead, S&P projects leverage will remain around 4x and forecasts robust annual free cash flow of $1.2 billion to $1.4 billion in 2025 and 2026, though ASC growth is expected to moderate. While potential health policy changes present a risk, S&P believes Tenet has sufficient cushion to absorb impacts at the new rating level.

Key Decisions for Investors

• The S&P credit upgrade to 'BB-' with a positive outlook serves as a strong confirmation of Tenet's successful business model transformation and deleveraging, providing a key positive data point for the bull case.
• Investors should now focus on management's capital deployment strategy, as the use of the projected $1.2 billion to $1.4 billion in annual free cash flow will be the primary determinant of further credit improvements and shareholder returns.
• Monitor the pace of growth in the high-margin ASC segment, which management indicated will slow, and watch for any material impact from pending health policy developments, which S&P has identified as a key risk factor to the outlook.